相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo et al.
LIVER CANCER (2021)
Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective
Masatoshi Kudo
HEPATOBILIARY SURGERY AND NUTRITION (2021)
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Jiajie Hou et al.
JOURNAL OF HEPATOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Calin Cainap et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2014)
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Virginia Hernandez-Gea et al.
GASTROENTEROLOGY (2013)
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann-Lii Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
JL Steel et al.
ANNALS OF ONCOLOGY (2006)